Lexeo Therapeutics, Inc
Price
FilingsNewest: 8-K, Acquisition or sale of assetsSep 29 →InsidersNo open-market buys. 5 insiders sold $685,183, 1 of 20 sales on a 10b5-1 plan.→HoldersMontanova Capital 8.1%Affinity Asset 7.4%BlackRock 7.3%→Financing →PeersClosest companies: PASG, TNYA, DYN→
From the filings
Figures
- Net income
- −$87.3Mlast 12 months
- Operating cash flow
- −$98.0Mlast 12 months
- Cash and equivalents
- $92.8Mat the last balance sheet
- Shares outstanding
- 78.6M shareson issue